{"name":"Chun-Yao Huang","slug":"chun-yao-huang","ticker":"","exchange":"","domain":"","description":"Chun-Yao Huang is a pharmaceutical company with a focus on developing innovative therapies. The company has one drug in Phase 3 clinical trials, Ivabradine 5 mg [Corlanor], which is aimed at addressing cardiovascular conditions.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9ieENhR2NUVTFBRVIzZUZZdVZNaG81NVdVYzMtazFGZ1daa3phQnBXUDlpaEpUSU0zal9TVV83QnVHUGFmNmdzdFFSSWVaN2p1NE1Wd25EMnRLOVNUQV9F?oc=5","date":"2025-08-02","type":"trial","source":"Nature","summary":"Glycemic levels and cardiovascular events in type 2 diabetes: A cohort study of drugs with different hypoglycemic potentials - Nature","headline":"Glycemic levels and cardiovascular events in type 2 diabetes: A cohort study of drugs with different hypoglycemic potent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9GdGpJV0FaQk9xcTE5b0hKcGhtZzJqWmNkS25leUpMUVhsa1NaX0FYX05jeEFXZWJ2bFVfYkw2ckFYVE1HV3NvNzdET1ZjbGVTSkxrSHZJY2lXOHBRS0hN?oc=5","date":"2025-07-09","type":"pipeline","source":"Nature","summary":"Clinical impact of pharmacogenetic risk variants in a large chinese cohort - Nature","headline":"Clinical impact of pharmacogenetic risk variants in a large chinese cohort","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}